A comparison of platelet quality between platelets from healthy donors and hereditary hemochromatosis donors over seven‐day storage. Issue 1 (9th November 2020)

• Record Type: Journal Article
• Authors: Mikaelsdottir, Marta; Vidarsson, Brynjar; Runarsson, Gudmundur; Bjarnadottir, Una; Onundarson, Pall T.; Sigurjonsson, Olafur E.; Halldorsdottir, Anna M.
• Is Part Of: Transfusion. Volume 61:Issue 1(2021)
• Page Start: 202
• Page End: 211
• Publication Date: 2020-11-09
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.16176
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract: Background: Therapeutic phlebotomy is the standard treatment of hereditary hemochromatosis (HH), the most common genetic disease in people of Northern European descent. Red cell concentrates from HH donors have been reported safe for transfusion, but little data is available on the storage properties of platelet concentrates from HH donors. Study Design and Methods: Whole blood was collected from 10 healthy individuals and 10 newly diagnosed HH patients with elevated serum ferritin. Platelet‐rich plasma (PRP) was prepared and split into four 20‐mL units. Platelet quality tests were performed on days 0, 1, 3, 5, and 7 of storage, including platelet aggregation (ADP, arachidonic acid, collagen, and epinephrine agonists), blood gas analysis, flow cytometry (CD41, CD42b, and CD62P expression), and ELISA (sCD40L and sCD62p in supernatant). Results: Mean serum ferritin levels were higher in HH patients than in controls (847.5 vs 45.8 ng/mL, P < .001). Overall, no difference in quality test results was observed between the two study groups over 7‐day storage ( P > .05), including blood gas analysis, platelet aggregation, and expression of surface (CD62p and CD42b) and secreted (sCD62P and sCD40L) activation markers. Expected alterations in metabolic (CO2 and glucose decrease, O2 and lactate increase, P < .001) and platelet activation markers (CD42b decrease, CD62P increase, P < .05) over time were observed in both groups. Conclusion: Although these findings indicate that platelets of individuals with HH are comparable to platelets from healthy donors, more extensive studies are needed before definite conclusions can be drawn.